Patient Education
Share your love
Ocular Therapeutix Gets FDA Agreement for Wet AMD Trial
Ocular Therapeutix has obtained written FDA approval for the comprehensive design of its pivotal phase 3 clinical trial, known as the SOL trial, which evaluates Axpaxli (axitinib intravitreal implant) for treating wet age-related macular degeneration (AMD) under a Special Protocol…
Seeing Beyond: Community and Inclusion in Ophthalmology – Emory School of Medicine
Seeing Beyond: Community and Inclusion in Ophthalmology Emory School of Medicine Source: Author: | Date: 2023-11-01 13:42:00 Source: Author: | Date: 2023-11-01 13:42:00
FDA Greenlights Phase 1 Trial for IOPCL Magnifier
OnPoint Vision has officially received FDA approval for their investigational device exemption (IDE) application, initiating the phase 1 in the pivotal clinical trial for the AccuraSee Intraocular Pseudophakic Capsular Lens (IOPCL) Magnifier (MAG). This trial focuses on the secondary implantation…
Opthea Announces Key Leadership Changes for 2025 Launch
Opthea has announced key leadership appointments to strengthen its commercial and clinical capabilities as it prepares for the 2025 topline data readout of Phase 3 trials for sozinibercept, its lead candidate for wet AMD. New Leadership Appointments • Daniel Geffken –…
What Is Idiopathic Multifocal Choroiditis and How to Manage It|OBN
What Is Idiopathic Multifocal Choroiditis? Idiopathic Multifocal Choroiditis (IMFC) is a rare eye condition that primarily affects the choroid, a vascular layer situated between the retina and the sclera (the white part of the eye). The condition is characterized by…
Haag-Streit Launches of New Office in Japan
Haag-Streit has announced the launch of Haag-Streit Japan KK, strengthening its regional presence after recent expansions into China and Singapore. “Our expansion into Japan is a milestone in Haag-Streit’s international commercial expansion plan,” Dr. Stefan Haag, CMO of Haag-Streit Group…
Large-Scale Study Sheds Light on Rare Eye Disorders
Researchers have analyzed image and genomic data from the UK Biobank to find insights into rare diseases of the human eye. These include retinal dystrophies – a group of inherited disorders affecting the retina – which are also the leading…
Novartis CEO Denies Ophthalmology Unit Sell-off Rumors
At the J.P. Morgan Healthcare Conference, Novartis CEO Vas Narasimhan denied rumors that the pharmaceutical giant is planning to sell its respiratory and ophthalmology units altogether. The rumors, which have been circulating for several weeks, suggested that Novartis was looking…
Novartis Initiates Sale of Ophthalmology Assets
According to sources familiar with the matter, Novartis AG is kicking off the process of selling some of its ophthalmology assets in order to prune its portfolio and concentrate on other therapeutic areas, including hematology, immunology, solid tumors, neurology, and…
Bausch + Lomb Acquires Eye Drugs from Novartis
Bausch + Lomb has announced that it will acquire the dry eye drug Xiidra (lifitegrast ophthalmic solution) 5% from Novartis. Xiidra is an eye drop without steroids that has received specific approval for treating the signs and symptoms of dry…